|
1
|
Sathianathen NJ, Konety BR, Crook J, Saad
F and Lawrentschuk N: Landmarks in prostate cancer. Nat Rev Urol.
15:627–642. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Baciarello G, Gizzi M and Fizazi K:
Advancing therapies in metastatic castration-resistant prostate
cancer. Expert Opin Pharmacother. 19:1797–1804. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Liu FT and Rabinovich GA: Galectins as
modulators of tumour progression. Nat Rev Cancer. 5:29–41. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Thijssen VL, Heusschen R, Caers J and
Griffioen AW: Galectin expression in cancer diagnosis and
prognosis: A systematic review. Biochim Biophys Acta. 1855:235–247.
2015.PubMed/NCBI
|
|
5
|
Laderach DJ, Gentilini LD, Giribaldi L,
Delgado VC, Nugnes L, Croci DO, Al Nakouzi N, Sacca P, Casas G,
Mazza O, et al: A unique galectin signature in human prostate
cancer progression suggests galectin-1 as a key target for
treatment of advanced disease. Cancer Res. 73:86–96. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Compagno D, Gentilini LD, Jaworski FM,
Pérez IG, Contrufo G and Laderach DJ: Glycans and galectins in
prostate cancer biology, angiogenesis, and metastasis.
Glycobiology. 24:899–906. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Martínez-Bosch N, Rodriguez-Vida A,
Juanpere N, Lloreta J, Rovira A, Albanell J, Bellmunt J and Navarro
P: Galectins in prostate and bladder cancer: Tumorigenic roles and
clinical opportunities. Nat Rev Urol. 16:433–445. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ahmed H, Cappello F, Rodolico V and Vasta
GR: Evidence of heavy methylation in the galectin 3 promoter in
early stages of prostate adenocarcinoma: Development and validation
of a methylated marker for early diagnosis of prostate cancer.
Transl Oncol. 2:146–156. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ellerhorst J, Troncoso P, Xu XC, Lee J and
Lotan R: Galectin-1 and galectin-3 expression in human prostate
tissue and prostate cancer. Urol Res. 27:362–367. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Pacis RA, Pilat MJ, Pienta KJ, Wojno K,
Raz A, Hogan V and Cooper CR: Decreased galectin-3 expression in
prostate cancer. Prostate. 44:118–123. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
van den Brûle FA, Waltregny D, Liu FT and
Castronovo V: Alteration of the cytoplasmic/nuclear expression
pattern of galectin-3 correlates with prostate carcinoma
progression. Int J Cancer. 89:361–367. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Merseburger AS, Kramer MW, Hennenlotter J,
Simon P, Knapp J, Hartmann JT, Stenzl A, Serth J and Kuczyk MA:
Involvement of decreased Galectin-3 expression in the pathogenesis
and progression of prostate cancer. Prostate. 68:72–77. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang Y, Nangia-Makker P, Tait L, Balan V,
Hogan V, Pienta KJ and Raz A: Regulation of prostate cancer
progression by galectin-3. Am J Pathol. 174:1515–1523. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
de Melo-Júnior MR, Araújo-Filho JL, Lins
CA, de Pontes-Filho NT and de Carvalho LB Jr: Immobilization of
anti-galectin-3 onto polysiloxane-polyvinyl alcohol disks for tumor
prostatic diseases diagnosis. Appl Biochem Biotechnol.
160:2198–2207. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Knapp JS, Lokeshwar SD, Vogel U,
Hennenlotter J, Schwentner C, Kramer MW, Stenzl A and Merseburger
AS: Galectin-3 expression in prostate cancer and benign prostate
tissues: Correlation with biochemical recurrence. World J Urol.
31:351–358. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Geisler C, Gaisa NT, Pfister D, Fuessel S,
Kristiansen G, Braunschweig T, Gostek S, Beine B, Diehl HC, Jackson
AM, et al: Identification and validation of potential new
biomarkers for prostate cancer diagnosis and prognosis using
2D-DIGE and MS. Biomed Res Int. 2015:4542562015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ahmed H, Banerjee PP and Vasta GR:
Differential expression of galectins in normal, benign, and
malignant prostate epithelial cells: Silencing of galectin-3
expression in prostate cancer by its promoter methylation. Biochem
Biophys Res Commun. 358:241–246. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Califice S, Castronovo V, Bracke M and van
den Brûle F: Dual activities of galectin-3 in human prostate
cancer: Tumor suppression of nuclear galectin-3 vs tumor promotion
of cytoplasmic galectin-3. Oncogene. 23:7527–7536. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Fukumori T, Oka N, Takenaka Y,
Nangia-Makker P, Elsamman E, Kasai T, Shono M, Kanayama HO,
Ellerhorst J, Lotan R and Raz A: Galectin-3 regulates mitochondrial
stability and antiapoptotic function in response to anticancer drug
in prostate cancer. Cancer Res. 66:3114–3119. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang Y, Nangia-Makker P, Balan V, Hogan V
and Raz A: Calpain activation through galectin-3 inhibition
sensitizes prostate cancer cells to cisplatin treatment. Cell Death
Dis. 1:e1012010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang Y, Balan V, Gao X, Reddy PG, Kho D,
Tait L and Raz A: The significance of galectin-3 as a new basal
cell marker in prostate cancer. Cell Death Dis. 4:e7532013.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Guha P, Kaptan E, Bandyopadhyaya G,
Kaczanowska S, Davila E, Thompson K, Martin SS, Kalvakolanu DV,
Vasta GR and Ahmed H: Cod glycopeptide with picomolar affinity to
galectin-3 suppresses T-cell apoptosis and prostate cancer
metastasis. Proc Natl Acad Sci USA. 110:5052–5057. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Glinsky VV, Glinsky GV, Rittenhouse-Olson
K, Huflejt ME, Glinskii OV, Deutscher SL and Quinn TP: The role of
Thomsen-Friedenreich antigen in adhesion of human breast and
prostate cancer cells to the endothelium. Cancer Res. 61:4851–4857.
2001.PubMed/NCBI
|
|
24
|
Glinsky VV, Glinsky GV, Glinskii OV,
Huxley VH, Turk JR, Mossine VV, Deutscher SL, Pienta KJ and Quinn
TP: Intravascular metastatic cancer cell homotypic aggregation at
the sites of primary attachment to the endothelium. Cancer Res.
63:3805–3811. 2003.PubMed/NCBI
|
|
25
|
Dondoo TO, Fukumori T, Daizumoto K, Fukawa
T, Kohzuki M, Kowada M, Kusuhara Y, Mori H, Nakatsuji H, Takahashi
M and Kanayama HO: Galectin-3 is implicated in tumor progression
and resistance to anti-androgen drug through regulation of androgen
receptor signaling in prostate cancer. Anticancer Res. 37:125–134.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Farhad M, Rolig AS and Redmond WL: The
role of Galectin-3 in modulating tumor growth and immunosuppression
within the tumor microenvironment. Oncoimmunology. 7:e14344672018.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Dumic J, Dabelic S and Flögel M:
Galectin-3: An open-ended story. Biochim Biophys Acta.
1760:616–635. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang L and Guo XL: Molecular regulation of
galectin-3 expression and therapeutic implication in cancer
progression. Biomed Pharmacother. 78:165–171. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ruebel KH, Jin L, Qian X, Scheithauer BW,
Kovacs K, Nakamura N, Zhang H, Raz A and Lloyd RV: Effects of DNA
methylation on galectin-3 expression in pituitary tumors. Cancer
Res. 65:1136–1140. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Heldring N, Pike A, Andersson S, Matthews
J, Cheng G, Hartman J, Tujague M, Ström A, Treuter E, Warner M and
Gustafsson JA: Estrogen receptors: How do they signal and what are
their targets. Physiol Rev. 87:905–931. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Thiebaut C, Vlaeminck-Guillem V, Trédan O,
Poulard C and Le Romancer M: Non genomic signaling of steroid
receptors in cancer. Mol Cell Endocrinol. 538:1114532021.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Pisolato R, Lombardi AP, Vicente CM, Lucas
TF, Lazari MF and Porto CS: Expression and regulation of the
estrogen receptors in PC-3 human prostate cancer cells. Steroids.
107:74–86. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Souza DS, Lombardi A, Vicente CM, Lucas T,
Erustes AG, Pereira G and Porto CS: Estrogen receptors localization
and signaling pathways in DU-145 human prostate cancer cells. Mol
Cell Endocrinol. 483:11–23. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lombardi AP, Pisolato R, Vicente CM,
Lazari MF, Lucas TF and Porto CS: Estrogen receptor beta (ERβ)
mediates expression of β-catenin and proliferation in prostate
cancer cell line PC-3. Mol Cell Endocrinol. 430:12–24. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lombardi A, Cavalheiro RP, Porto CS and
Vicente CM: Estrogen receptor signaling pathways involved in
invasion and colony formation of androgen-independent prostate
cancer cells PC-3. Int J Mol Sci. 22:11532021. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Silva RS, Lombardi A, Souza DS, Vicente CM
and Porto CS: Activation of estrogen receptor beta (ERβ) regulates
the expression of N-cadherin, E-cadherin and β-catenin in
androgen-independent prostate cancer cells. Int J Biochem Cell
Biol. 96:40–50. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Stauffer SR, Coletta CJ, Tedesco R,
Nishiguchi G, Carlson K, Sun J, Katzenellenbogen BS and
Katzenellenbogen JA: Pyrazole ligands: Structure-affinity/activity
relationships and estrogen receptor-alpha-selective agonists. J Med
Chem. 43:4934–4947. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Meyers MJ, Sun J, CarlsonK E, Marriner GA,
Katzenellenbogen BS and Katzenellenbogen JA: Estrogen receptor-beta
potency-selective ligands: Structure-activity relationship studies
of diarylpropionitriles and their acetylene and polar analogues. J
Med Chem. 44:4230–4251. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Bustos SO, da Silva Pereira GJ, de Freitas
Saito R, Gil CD, Zanatta DB, Smaili SS and Chammas R: Galectin-3
sensitized melanoma cell lines to vemurafenib (PLX4032) induced
cell death through prevention of autophagy. Oncotarget.
9:14567–14579. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lombardi A, Vicente CM and Porto CS:
Estrogen receptors promote migration, invasion and colony formation
of the androgen-independent prostate cancer cells PC-3 through
β-catenin pathway. Front Endocrinol. 11:1842020. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Vicente CM, Lima MA, Yates EA, Nader HB
and Toma L: Enhanced tumorigenic potential of colorectal cancer
cells by extracellular sulfatases. Mol Cancer Res. 13:510–523.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Marchiori MF, Riul TB, Oliveira Bortot L,
Andrade P, Junqueira GG, Foca G, Doti N, Ruvo M, Dias-Baruffi M,
Carvalho I and Campo VL: Binding of triazole-linked galactosyl
arylsulfonamides to galectin-3 affects Trypanosoma cruzi cell
invasion. Bioorg Med Chem. 25:6049–6059. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wang Y, Jing Y, Ding L, Zhang X, Song Y,
Chen S, Zhao X, Huang X, Pu Y, Wang Z, et al: Epiregulin reprograms
cancer-associated fibroblasts and facilitates oral squamous cell
carcinoma invasion via JAK2-STAT3 pathway. J Exp Clin Cancer Res.
38:2742019. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Macheroni C, Gameiro Lucas TF, Souza DS,
Vicente CM, Pereira GJDS, Junior IDSV, Juliano MA and Porto CS:
Activation of estrogen receptor ESR1 and ESR2 induces proliferation
of the human testicular embryonal carcinoma NT2/D1 cells. Mol Cell
Endocrinol. 554:1117082022. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Nelson AW, Tilley WD, Neal DE and Carroll
JS: Estrogen receptor beta in prostate cancer: Friend or foe?
Endocr Relat Cancer. 21:T219–T234. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Lau KM and To KF: Importance of estrogenic
signaling and its mediated receptors in prostate cancer. Int J Mol
Sci. 17:14342016. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Kowalska K and Piastowska-Ciesielska AW:
Oestrogens and oestrogen receptors in prostate cancer. Springer
Plus. 5:5222016. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Warner M, Fan X, Strom A, Wu W and
Gustafsson JÅ: 25 years of ERβ: A personal journey. J Mol
Endocrinol. 68:R1–R9. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Nelson AW, Groen AJ, Miller JL, Warren AY,
Holmes KA, Tarulli GA, Tilley WD, Katzenellenbogen BS, Hawse JR,
Gnanapragasam VJ and Carroll JS: Comprehensive assessment of
estrogen receptor beta antibodies in cancer cell line models and
tissue reveals critical limitations in reagent specificity. Mol
Cell Endocrinol. 440:138–150. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Semenas J, Wang T, Sajid Syed Khaja A,
Firoj Mahmud A, Simoulis A, Grundström T, Fällman M and Persson JL:
Targeted inhibition of ERα signaling and PIP5K1α/Akt pathways in
castration-resistant prostate cancer. Mol Oncol. 15:968–986. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Rossi V, Di Zazzo E, Galasso G, De Rosa C,
Abbondanza C, Sinisi AA, Altucci L, Migliaccio A and Castoria G:
Estrogens modulate somatostatin receptors expression and synergize
with the somatostatin analog pasireotide in prostate cells. Front
Pharmacol. 10:282019. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Leung YK, Lam HM, Wu S, Song D, Levin L,
Cheng L, Wu CL and Ho SM: Estrogen receptor beta2 and beta5 are
associated with poor prognosis in prostate cancer and promote
cancer cell migration and invasion. Endocr Relat Cancer.
17:675–689. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Gustafsson JA, Strom A and Warner M:
Update on ERbeta. J Steroid Biochem Mol Biol. 191:1053122019.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Kadrofske MM, Openo KP and Wang JL: The
human LGALS3 (galectin 3) gene: Determination of the gene structure
and functional characterization of the promoter. Arch Biochem
Biophys. 349:7–20. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Yang H, Lei C, Cheng C, Feng Y, Zhang W,
Petracco RG and Sak S: The Antiapoptotic effect of Galectin-3 in
human endometrial cells under the regulation of estrogen and
progesterone. Biol Reprod. 87:392012. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Bima C, Chiloiro S, Giampietro A, Gessi M,
Mattogno PP, Lauretti L, Anile C, Rindi G, Pontecorvi A, De Marinis
L and Bianchi A: Galectin-3 and estrogen receptor alpha as
prognostic markers in prolactinoma: Preliminary results from a
pilot study. Front Endocrinol (Lausanne). 12:6840552021. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Mourad-Zeidan AA, Melnikova VO, Wang H,
Raz A and Bar-Eli M: Expression profiling of Galectin-3-depleted
melanoma cells reveals its major role in melanoma cell plasticity
and vasculogenic mimicry. Am J Pathol. 173:1839–1852. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Wang YG, Kim SJ, Baek JH, Lee HW, Jeong SY
and Chun KH: Galectin-3 increases the motility of mouse melanoma
cells by regulating matrix metalloproteinase-1 expression. Exp Mol
Med. 44:387–393. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Shimura T, Takenaka Y, Tsutsumi S, Hogan
V, Kikuchi A and Raz A: Galectin-3, a novel binding partner of
beta-catenin. Cancer Res. 64:6363–6367. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Yang Y, Zhou Z, He S, Fan T, Jin Y, Zhu X,
Chen C, Zhang ZR and Huang Y: Treatment of prostate carcinoma with
(galectin-3)-targeted HPMA copolymer-(G3-C12)-5-Fluorouracil
conjugates. Biomaterials. 33:2260–2271. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Glinsky VV and Raz A: Modified citrus
pectin anti-metastatic properties: One bullet, multiple targets.
Carbohydr Res. 344:1788–1791. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Conti S, Vexler A, Hagoel L,
Kalich-Philosoph L, Corn BW, Honig N, Shtraus N, Meir Y, Ron I,
Eliaz I and Lev-Ari S: Modified citrus pectin as a potential
sensitizer for radiotherapy in prostate cancer. Integr Cancer Ther.
17:1225–1234. 2018. View Article : Google Scholar : PubMed/NCBI
|
